The ingestion of Ginkgo biloba extract (EGb 761) inhibits arachidonic acid-mediated platelet aggregation and thromboxane B2 production in healthy volunteers

George B. Kudolo, Wen Wang, Jessica Barrientos, Ryan Elrod, Janet Blodgett

Research output: Contribution to journalArticle

24 Scopus citations

Abstract

Twelve non-diabetic volunteers (age = 39 ± 13 years, BMI = 23.5 ± 3.5) undertook a randomized double-blind placebo-controlled crossover study in which they ingested either 120 mg of EGb 761 or a placebo daily for 3 months and then switched to the other test capsules for the next 3 months. Platelet aggregation in platelet-rich plasma (PRP) was performed at the end of each 3-month arm, with or without 1-min incubation with graded doses of EGb 761. In the placebo cycles, AA-stimulated TXB2 production was 2581 ± 1337 pg/106 platelets (range 897-5485) compared to 1668 ± 992 pg/106 platelets (range 6-1668) in the EGb 761 cycles (p < 0.005). Incubation of PRP with EGb 761 (150 μg/ml) completely inhibited platelet aggregation accompanied by inhibition of TXB2 synthesis in all subjects both in the placebo (< 200 pg TXB2/106 platelets) and EGb 761 cycles (< 120 TXB2/106 platelets) (p < 0.0001). These results results EGb 761-mediated inhibition of platelet TXB2 synthesis in vivo.

Original languageEnglish (US)
Pages (from-to)13-26
Number of pages14
JournalJournal of Herbal Pharmacotherapy
Volume4
Issue number4
DOIs
StatePublished - Dec 1 2004

Keywords

  • Ginkgo biloba extract
  • Platelet aggregation
  • Thromboxane B

ASJC Scopus subject areas

  • Pharmacology

Fingerprint Dive into the research topics of 'The ingestion of Ginkgo biloba extract (EGb 761) inhibits arachidonic acid-mediated platelet aggregation and thromboxane B<sub>2</sub> production in healthy volunteers'. Together they form a unique fingerprint.

  • Cite this